title: Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation.
abstract: BACKGROUND
  With the development of sensitive tests to detect cytomegalovirus (CMV) viremia, preemptive approaches become a reasonable alternative to general CMV prophylaxis. We performed a randomized trial comparing pp65-antigenemia guided preemptive therapy using oral ganciclovir with symptom-triggered intravenous ganciclovir treatment.
  
  
  METHODS
  Eighty-eight of 372 liver transplant recipients developed antigenemia early after orthotopic liver transplantation. Twenty-eight symptomatic patients with antigenemia were excluded from randomization and treated with intravenous ganciclovir. Sixty pp65-antigen-positive asymptomatic patients were randomized to receive either oral ganciclovir 3x1 g/day for 14 days (group 1) or no preemptive treatment (group 2). Patients that developed CMV disease were treated with intravenous ganciclovir 2x5 mg/kg body weight for 14 days. The high-risk (Donor+/Recipient-) patients were equally distributed in the two study groups.
  
  
  RESULTS
  Three of 30 (10%) patients on oral ganciclovir developed mild to moderate CMV disease compared with 6/30 (20%) patients in the control group. In the Donor+/Recipient- patients, the incidence of CMV disease was 1/6 and 3/7. All disease episodes resolved after intravenous treatment. The 1- and 3-year patient and organ survival was the same in the study groups and in the patients with or without CMV infection. No deaths related to CMV occurred.
  
  
  CONCLUSIONS
  The positive predictive value of pp65-antigenemia for the development of CMV disease was very low, and, in 28/88 patients (32%), antigenemia did not precede symptoms. Therefore, pp65-antigenemia is of limited value in deciding on the timing and need for ganciclovir therapy after liver transplantation.
authors.affiliation: Department of Surgery, Charité Campus Virchow, Augustenburger Platz 1, 13355 Berlin, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Rayes
authors.forename: D
authors.initials: D
authors.lastname: Seehofer
authors.forename: C A
authors.initials: CA
authors.lastname: Schmidt
authors.forename: H
authors.initials: H
authors.lastname: Oettle
authors.forename: A R
authors.initials: AR
authors.lastname: Müller
authors.forename: T
authors.initials: T
authors.lastname: Steinmüller
authors.forename: U
authors.initials: U
authors.lastname: Settmacher
authors.forename: W O
authors.initials: WO
authors.lastname: Bechstein
authors.forename: P
authors.initials: P
authors.lastname: Neuhaus
mesh_terms: D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007275:Injections, Intravenous; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010750:Phosphoproteins / Q000097:blood; D011446:Prospective Studies; D012008:Recurrence; D012086:Reoperation; D015996:Survival Rate; D014763:Viral Matrix Proteins / Q000097:blood; D014766:Viremia / Q000188:drug therapy / Q000209:etiology
chemical_list: D000998:Antiviral Agents; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa; D015774:Ganciclovir